GlassScriptPhysician profile
Holly Dushkin
NPI 1336279215
$7,045.69
in general payments reported to CMS, 2019-2025
57 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,247 · 2022: $1,018 · 2023: $1,470 · 2024: $1,638 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,167.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.88 | 2021-2025 | Imfinzi, Calquence, Lynparza |
| Pfizer INC. | $433.22 | 2021-2025 | |
| Janssen Biotech, INC. | $349.40 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Daiichi Sankyo INC. | $320.75 | 2022-2025 | Enhertu, Injectafer |
| Secura Bio, INC. | $316.33 | 2021 | |
| Merck Sharp & Dohme LLC | $158.76 | 2021-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $152.45 | 2022-2025 | Opdivo |
| Stemline Therapeutics INC. | $149.01 | 2023-2025 | Orserdu |
| Eisai INC. | $146.35 | 2021-2024 | |
| Lilly USA, LLC | $136.63 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Ge Healthcare | $133.48 | 2021-2022 | |
| Puma Biotechnology, INC. | $133.48 | 2022-2025 | |
| Abbvie INC. | $129.73 | 2022-2024 | Venclexta |
| Genentech USA, INC. | $122.20 | 2021-2025 | Tecentriq, Gazyva, Perjeta |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $115.26 | 2022-2024 | Besremi |
| Array Biopharma INC | $113.07 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Amgen INC. | $109.20 | 2022-2023 | Lumakras, Nplate, Vectibix |
| Exelixis INC. | $106.79 | 2024-2025 | Cabometyx |
| Celgene Corporation | $106.72 | 2022-2024 | Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $105.90 | 2024 | Alunbrig, Ninlaro, Fruzaqla |
| Beigene USA, INC. | $95.38 | 2022-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $94.58 | 2023 | Imbruvica, Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.88 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $86.64 | 2022-2025 | Monoferric |
| Astellas Pharma US INC | $84.20 | 2022-2024 | Padcev |
| Gilead Sciences, INC. | $83.05 | 2021-2024 | |
| Coherus Oncology, INC. | $81.37 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.22 | 2023 | |
| Emd Serono, INC. | $80.14 | 2022-2025 | |
| Aveo Pharmaceuticals, INC. | $78.07 | 2023-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $72.69 | 2022-2023 | Onivyde, Somatuline Depot |
| Taiho Oncology, INC. | $72.29 | 2021-2023 | |
| Tersera Therapeutics LLC | $69.94 | 2023-2024 | Xermelo, Zoladex |
| Morphosys, US INC. | $68.61 | 2022-2024 | Monjuvi |
| Genzyme Corporation | $62.96 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $60.80 | 2023-2024 | Xpovio |
| Geron Corporation | $56.25 | 2025 | Rytelo |
| Incyte Corporation | $52.00 | 2023-2025 | Jakafi, Niktimvo |
| Adc Therapeutics America, INC. | $49.54 | 2024 | |
| G1 Therapeutics, INC. | $47.33 | 2022-2023 | Cosela |
| Spectrum Pharmaceuticals INC. | $45.15 | 2025 | Rolvedon |
| Celltrion USA INC. | $41.73 | 2023 | Vegzelma |
| Acrotech Biopharma INC. | $38.27 | 2023-2024 | Beleodaq |
| Novocure INC. | $36.80 | 2025 | Optune Lua (Novottf-200t) |
| Beone Medicines USA, INC. | $33.96 | 2025 | Tevimbra |
| Regeneron Healthcare Solutions, INC. | $33.45 | 2025 | Libtayo |
| Genmab U.S., INC. | $30.75 | 2024 | Epkinly |
| Legend Biotech USA INC. | $29.80 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $28.86 | 2024 | Ojjaara |
| Janssen Pharmaceuticals, INC | $25.20 | 2024 | Xarelto |
| Sobi, INC | $24.55 | 2022 | |
| Eusa Pharma (US) LLC | $22.80 | 2021 | |
| Kite Pharma, INC. | $22.05 | 2021 | |
| Blueprint Medicines Corporation | $21.00 | 2022 | |
| Heron Therapeutics, INC. | $20.26 | 2022 | |
| Foundation Medicine, INC. | $13.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Dushkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.